2024
Comparing the brief Holistic Health for HIV (3H+) to the Holistic Health Recovery Program (HHRP+) among people with HIV and opioid use disorder: Results from a randomized, controlled non-inferiority trial
Zelenev A, Huedo-Medina T, Shrestha R, Mistler C, Altice F, Sibilio B, Copenhaver M. Comparing the brief Holistic Health for HIV (3H+) to the Holistic Health Recovery Program (HHRP+) among people with HIV and opioid use disorder: Results from a randomized, controlled non-inferiority trial. PLOS ONE 2024, 19: e0312165. PMID: 39509356, PMCID: PMC11542883, DOI: 10.1371/journal.pone.0312165.Peer-Reviewed Original ResearchConceptsHolistic Health Recovery ProgramEvidence-based interventionsHolistic healthHIV treatmentRisk behaviorsReduce HIV risk behaviorsDifference-in-differencesEnd-of-interventionControlled non-inferiority trialHIV Epidemic goalsDrug treatment settingsAttainment of viral suppressionNon-inferiority trialRecovery programViral suppressionHigh ART adherenceHIV risk behaviorsNon-inferiorityHHRP+ART adherenceBehavioral interventionsReal-world settingsNon-parametric bootstrappingCondom useOpioid-dependent people
2018
Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine
Mazhnaya A, Marcus R, Bojko MJ, Zelenev A, Makarenko I, Pykalo I, Filippovych S, Dvoriak S, Altice FL. Opioid Agonist Treatment and Improved Outcomes at Each Stage of the HIV Treatment Cascade in People Who Inject Drugs in Ukraine. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 288-295. PMID: 30312275, PMCID: PMC8215524, DOI: 10.1097/qai.0000000000001827.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentHIV treatment cascadeTreatment cascadeAgonist treatmentIndependent factorsHepatitis C virus testingOpioid-dependent PWIDOpioid use disorderClinical care settingsLogistic regression modelsOAT coverageAntiretroviral therapyHIV careUNAIDS 90HIV preventionImproved outcomesTreatment strategiesCare settingsVirus testingNationwide studyPWIDUse disordersOAT expansionHIVCareAssessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine
Zelenev A, Shea P, Mazhnaya A, Rozanova J, Madden L, Marcus R, Altice FL. Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug And Alcohol Dependence 2018, 190: 82-88. PMID: 29990648, PMCID: PMC6292439, DOI: 10.1016/j.drugalcdep.2018.05.027.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid agonist treatmentOpioid-dependent peopleSubstance abuse treatment programsCross-sectional surveyAgonist therapyAgonist treatmentHIV preventionTreatment perceptionsTreatment efficacyOAT expansionStudy participantsTreatment programAddiction treatmentComposite measureSeveritySocial stigmaDrugsTreatmentStructural barriersBarrier severityParticipants
2017
Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study
Zelenev A, Li J, Mazhnaya A, Basu S, Altice FL. Hepatitis C virus treatment as prevention in an extended network of people who inject drugs in the USA: a modelling study. The Lancet Infectious Diseases 2017, 18: 215-224. PMID: 29153265, PMCID: PMC5860640, DOI: 10.1016/s1473-3099(17)30676-x.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAntiviral AgentsChemopreventionCitiesComputer SimulationDisease Transmission, InfectiousFemaleHepatitis CHumansMaleMiddle AgedModels, StatisticalPrevalenceSubstance Abuse, IntravenousSurveys and QuestionnairesTime FactorsTreatment OutcomeUnited StatesYoung AdultConceptsBaseline HCV prevalenceHepatitis C virusHCV prevalenceInjection partnersPrevention strategiesTreatment coverageTransmission of HCVHepatitis C virus (HCV) treatmentHCV elimination strategySuccessful HCV treatmentC virus treatmentInjection drug usersHCV treatment coverageAdditional network memberHCV treatmentActing antiviralsC virusChronic infectionVirus treatmentDrug usersPrevalenceDrug abuseDrugsNational InstitutePreventionOverlooked Threats to Respondent Driven Sampling Estimators: Peer Recruitment Reality, Degree Measures, and Random Selection Assumption
Li J, Valente TW, Shin HS, Weeks M, Zelenev A, Moothi G, Mosher H, Heimer R, Robles E, Palmer G, Obidoa C. Overlooked Threats to Respondent Driven Sampling Estimators: Peer Recruitment Reality, Degree Measures, and Random Selection Assumption. AIDS And Behavior 2017, 22: 2340-2359. PMID: 28660381, PMCID: PMC5745307, DOI: 10.1007/s10461-017-1827-1.Peer-Reviewed Original Research
2016
The complex interplay of social networks, geography and HIV risk among Malaysian Drug Injectors: Results from respondent-driven sampling
Zelenev A, Long E, Bazazi AR, Kamarulzaman A, Altice FL. The complex interplay of social networks, geography and HIV risk among Malaysian Drug Injectors: Results from respondent-driven sampling. International Journal Of Drug Policy 2016, 37: 98-106. PMID: 27639995, PMCID: PMC5102779, DOI: 10.1016/j.drugpo.2016.08.008.Peer-Reviewed Original ResearchConceptsHIV statusHIV transmissionClean needlesRecent injection partnersHigh-risk populationRisk reduction interventionsTargeting of interventionsPublic health surveillanceRespondent-driven samplingInjection partnersHIV preventionHIV riskTreatment coverageDrug injectorsHIVPrevention strategiesPWIDHealth surveillanceGreater Kuala LumpurKuala LumpurInterventionSurveillanceImportant mechanismStatus